Adds nine additional countries to the Company’s ongoing pivotal Phase 3 trial; Authorization granted in all EU countries ...

The European Medicines Agency (EMA) has approved Moleculin Biotech’s clinical trial application (CTA) for a pivotal, ...

Adds nine additional countries to the Company's ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested Enrollment and dosing underway in Phase 3 clinical trial (the "MIRACL ...

The HIV Clinical Trials Market focuses on the systematic evaluation of novel antiretroviral therapies, combination regimens, long-acting injectables, and immunotherapeutic approaches to control and ...

Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to comp ...

pivotal Phase 2/3 adaptive design clinical trial to support potential BLA submission Company to host conference call and webcast today at 4:30 p.m. ET MIAMI, May 08, 2025 (GLOBE NEWSWIRE ...

Retail chatter around Moleculin Biotech surged on Monday after the company said the European Medicines Agency had approved ...

Annamycin has the potential to be safer and more effective than current prescribed anthracyclines to treat serious, ...

Meeting to Take Place on July 25, 2025 Meeting’s Purpose is To Discuss Upcoming Clinical Development Plan and Protocol ...